Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR--All patients discontinued immunosuppressants –- All but one patient tapered background steroids to ≤5 mg prednisone
Adicet Bio tested a new cell therapy for lupus patients. Early results show the treatment was safe and helped many patients improve without needing other medicines.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.